Next Article in Journal
Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model
Next Article in Special Issue
Plant Virology Delivers Diverse Toolsets for Biotechnology
Previous Article in Journal
Role of CCCH-Type Zinc Finger Proteins in Human Adenovirus Infections
Previous Article in Special Issue
JSRV Intragenic Enhancer Element Increases Expression from a Heterologous Promoter and Promotes High Level AAV-Mediated Transgene Expression in the Lung and Liver of Mice
Review

Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19

PanTherapeutics, CH1095 Lutry, Switzerland
Received: 12 October 2020 / Revised: 16 November 2020 / Accepted: 17 November 2020 / Published: 18 November 2020
(This article belongs to the Special Issue The Application of Viruses to Biotechnology)
Viral vectors can generate high levels of recombinant protein expression providing the basis for modern vaccine development. A large number of different viral vector expression systems have been utilized for targeting viral surface proteins and tumor-associated antigens. Immunization studies in preclinical animal models have evaluated the elicited humoral and cellular responses and the possible protection against challenges with lethal doses of infectious pathogens or tumor cells. Several vaccine candidates for both infectious diseases and various cancers have been subjected to a number of clinical trials. Human immunization trials have confirmed safe application of viral vectors, generation of neutralizing antibodies and protection against challenges with lethal doses. A special emphasis is placed on COVID-19 vaccines based on viral vectors. Likewise, the flexibility and advantages of applying viral particles, RNA replicons and DNA replicon vectors of self-replicating RNA viruses for vaccine development are presented. View Full-Text
Keywords: viral vaccines; infectious diseases; cancers; COVID-19 vaccines; self-replicating RNA vectors; DNA-based vaccines; RNA-based vaccines viral vaccines; infectious diseases; cancers; COVID-19 vaccines; self-replicating RNA vectors; DNA-based vaccines; RNA-based vaccines
MDPI and ACS Style

Lundstrom, K. Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. Viruses 2020, 12, 1324. https://0-doi-org.brum.beds.ac.uk/10.3390/v12111324

AMA Style

Lundstrom K. Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. Viruses. 2020; 12(11):1324. https://0-doi-org.brum.beds.ac.uk/10.3390/v12111324

Chicago/Turabian Style

Lundstrom, Kenneth. 2020. "Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19" Viruses 12, no. 11: 1324. https://0-doi-org.brum.beds.ac.uk/10.3390/v12111324

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop